A Review of Dental Adverse Events Using the FDA Adverse Event Reporting System

被引：0
|
作者：
Altman, Keith [1 ]
Budny, Renata [2 ]
机构：
[1] Law Off Keith Altman, Massapequa Pk, NY USA
[2] New York City Coll Technol, Brooklyn, NY USA
来源：
PHARMACOEPIDEMIOLOGY AND DRUG SAFETY | 2014年 / 23卷
关键词：
D O I：
暂无
中图分类号：
R1 [预防医学、卫生学];
学科分类号：
1004 ; 120402 ;
摘要：
744
引用
收藏
页码：400 / 400
页数：1
相关论文
共 50 条
  • [1] Vedolizumab Adverse Events: Analysis of the FDA Adverse Event Reporting System
    Jow, Steven
    Hutfless, Susan
    [J]. INFLAMMATORY BOWEL DISEASES, 2017, 23 : S35 - S36
  • [2] Adverse Events of Desvenlafaxine Using FDA Adverse Events Reporting System
    Karydes, H. C.
    Leikin, J. B.
    [J]. CLINICAL TOXICOLOGY, 2010, 48 (06) : 664 - 664
  • [3] Evaluating Ubrogepant-related adverse events using the FDA adverse event reporting system
    Cao, Bing
    Gu, Shanshan
    Shen, Zhisen
    Zhang, Yuna
    Shen, Yiming
    Chen, Hang
    [J]. EXPERT OPINION ON DRUG SAFETY, 2023, : 297 - 303
  • [4] Comparative Analysis of Psychiatric Adverse Events of Brivaracetam and Levetiracetam Using the FDA Adverse Event Reporting System
    Porwal, Mokshal H.
    Shah, Ipsit
    Shah, Aneri N.
    Obeidat, Ahmed Z.
    [J]. ANNALS OF NEUROLOGY, 2022, 92 : S87 - S88
  • [5] Assessing taxane-associated adverse events using the FDA adverse event reporting system database
    Lao, Dong-Hui
    Chen, Ye
    Fan, Jun
    Zhang, Jian-Zhong
    [J]. CHINESE MEDICAL JOURNAL, 2021, 134 (12) : 1471 - 1476
  • [6] Indications and adverse events of teriparatide: based on FDA adverse event reporting system (FAERS)
    Wen, Ming-Tao
    Li, Jia-Cheng
    Lu, Bo-Wen
    Shao, Hua-Rong
    Ling, Pei-Xue
    Liu, Fei
    Li, Gang
    Luo, Di
    [J]. FRONTIERS IN PHARMACOLOGY, 2024, 15
  • [7] Adverse Events Associated with Fosfomycin Use: Review of the Literature and Analyses of the FDA Adverse Event Reporting System Database
    Iarikov D.
    Wassel R.
    Farley J.
    Nambiar S.
    [J]. Infectious Diseases and Therapy, 2015, 4 (4) : 433 - 458
  • [8] A pharmacovigilance analysis of FDA adverse event reporting system events for romosozumab
    Chen, Zepeng
    Li, Ming
    Li, Shuzhen
    Li, Yuxi
    Wu, Junyan
    Qiu, Kaifeng
    Yu, Xiaoxia
    Huang, Lin
    Chen, Guanghui
    [J]. EXPERT OPINION ON DRUG SAFETY, 2023, 22 (04) : 339 - 342
  • [9] Examining the Nocebo Effect of Statins Using Statin Adverse Events Reported in the FDA Adverse Event Reporting System
    Moon, Jungyeon
    Sedgh, Robert Cohen
    Jackevicius, Cynthia
    [J]. CIRCULATION, 2020, 142
  • [10] Adverse events associated with brolucizumab: a disproportionality analysis of the FDA adverse event reporting system (FAERS)
    Xiong, Xiaomei
    Zhang, Xiuwen
    Li, Xiaoxia
    Huang, Taomin
    [J]. EXPERT OPINION ON DRUG SAFETY, 2024,
12345